HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) has risen nearly 7%. The company has completed the localization deployment of an AI-driven antibody drug research and development platform.

Biocytogen Pharmaceuticals (02315) rose by nearly 7%, up 5.08% to HK$39.72 at the time of writing, with a turnover of HK$28.32 million. On the news front, Biocytogen Pharmaceuticals recently stated on an interactive platform that the company has completed the localization deployment of its AI-driven antibody drug research and development platform, and has achieved comprehensive synergy with the company's core business of the Thousand Mouse Million Antibody Program. Through the localization deployment of AI, the company is building an AI smart body for antibody drug research and development. As the integration of the Thousand Mouse Million Antibody Program with the AI system continues to progress, the company will provide more efficient research and development tools and a more extensive antibody molecular library for global pharmaceutical companies, helping pharmaceutical partners improve the efficiency of preclinical PCC molecule research and development, which will also drive the antibody discovery business into a new development stage.